Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.

BACKGROUND It is controversial whether prolonged antibiotic treatment is effective for patients in whom symptoms persist after the recommended antibiotic treatment for acute Lyme disease. METHODS We conducted two randomized trials: one in 78 patients who were seropositive for IgG antibodies to Borrelia burgdorferi at the time of enrollment and the other in 51 patients who were seronegative. The patients received either intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 200 mg daily for 60 days, or matching intravenous and oral placebos. Each patient had well-documented, previously treated Lyme disease but had persistent musculoskeletal pain, neurocognitive symptoms, or dysesthesia, often associated with fatigue. The primary outcome measures were improvement on the physical- and mental-health-component summary scales of the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36)--a scale measuring the health-related quality of life--on day 180 of the study. RESULTS After a planned interim analysis, the data and safety monitoring board recommended that the studies be discontinued because data from the first 107 patients indicated that it was highly unlikely that a significant difference in treatment efficacy between the groups would be observed with the planned full enrollment of 260 patients. Base-line assessments documented severe impairment in the patients' health-related quality of life. In intention-to-treat analyses, there were no significant differences in the outcomes with prolonged antibiotic treatment as compared with placebo. Among the seropositive patients who were treated with antibiotics, there was improvement in the score on the physical-component summary scale of the SF-36, the mental-component summary scale, or both in 37 percent, no change in 29 percent, and worsening in 34 percent; among seropositive patients receiving placebo, there was improvement in 40 percent, no change in 26 percent, and worsening in 34 percent (P=0.96 for the comparison between treatment groups). The results were similar for the seronegative patients. CONCLUSIONS There is considerable impairment of health-related quality of life among patients with persistent symptoms despite previous antibiotic treatment for acute Lyme disease. However, in these two trials, treatment with intravenous and oral antibiotics for 90 days did not improve symptoms more than placebo.

[1]  A. Weinstein,et al.  The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with post-Lyme disease syndrome. , 1999, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[2]  R. Bennett,et al.  Group treatment of fibromyalgia: a 6 month outpatient program. , 1996, The Journal of rheumatology.

[3]  K. Wells,et al.  The course of depression in adult outpatients. Results from the Medical Outcomes Study. , 1992, Archives of general psychiatry.

[4]  C. Schmid,et al.  A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. , 1996, Arthritis and rheumatism.

[5]  L. Mattman,et al.  A proposal for the reliable culture ofBorrelia burgdorferi from patients with chronic lyme disease, even from those previously aggressively treated , 1998, Infection.

[6]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[7]  M. Klempner,et al.  Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. , 1993, The Journal of infectious diseases.

[8]  C. Farrington,et al.  Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. , 1990, Statistics in medicine.

[9]  R. Bennett,et al.  A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. , 1998, The American journal of medicine.

[10]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[11]  M. Peterson,et al.  Lyme disease: an infectious and postinfectious syndrome. , 1994, The Journal of rheumatology.

[12]  W. Edwards,et al.  Death from inappropriate therapy for Lyme disease. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Ware SF-36 health survey: Manual and interpretation guide , 2003 .

[14]  S. Donta Tetracycline therapy for chronic Lyme disease. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Conaway,et al.  Responsiveness of fibromyalgia clinical trial outcome measures. , 2000, The Journal of rheumatology.

[16]  R M Bennett,et al.  The fibromyalgia impact questionnaire: development and validation. , 1991, The Journal of rheumatology.

[17]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[18]  S. Pillemer,et al.  Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial , 1995, Annals of Internal Medicine.

[19]  W H Rogers,et al.  Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. , 1996, JAMA.

[20]  A. Stewart,et al.  Measuring Functioning and Well-Being: The Medical Outcomes Study Approach , 1992 .

[21]  C. Sherbourne,et al.  Role Functioning Measures , 1992 .

[22]  C. Schmid,et al.  Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. , 1996, The Journal of infectious diseases.

[23]  R. Dornbush,et al.  Clinical and neurocognitive features of the post Lyme syndrome. , 1996, The Journal of rheumatology.

[24]  A. Steere,et al.  Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  John E. Ware,et al.  Psychological Distress/Well-Being and Cognitive Functioning Measures , 1992 .

[26]  A. Steere,et al.  Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. , 1990, The Journal of infectious diseases.